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Why Do Glucocorticoids Produce Potent and Persistent Diuresis Only in Subjects with Volume 
Overload Other Than Euvolemia 
-Diuresis Induced by Glucocorticoids Is Systemic Volume dependent 
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Heart Center, The First Hospital of Hebei Medical University, Hebei Medical University 
 
Background: The role of glucocorticoids in body fluid control is full of controversy. It is well documented that 
glucocorticoids could produce potent and persistent diuresis in congestive heart failure. But, the diuretic effect was 
not reported in patients with euvolemia.      
Objective: To test the hypothesis that the diuresis induced by glucocorticoids is systemic volume dependent.  
Methods: The diuretic effect of glucocorticoids in rats with various systemic volume statuses (i.e. systemic volume 
depletion, euvolemia, and systemic volume overload, respectively) was recorded.  
Results: glucocorticoids only produced potent and persistent diuresis in the rats with systemic volume overload. 
Conclusion: The diuresis induced by glucocorticoids was systemic volume dependent, which explained the 
phenomenon that glucocorticoids only have potent and persistent diuretic effect in congestive heart failure.   
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Every disturbance in the body evokes a stress 
response that serves to restore homeostasis. When 
exposing to stress, the hypothalamic-pituitary-adrenal 
system involving corticosteroid hormone secreted by 
the adrenals plays a crucial role in restoring 
homeostasis. It is well documented that hypothalamus 
plays a fundamental role in the body fluid control by 
secreting vasopressin and oxytocin in response to 
osmotic/nonosmotic stimuli. Newly emerged evidence 
showed that corticosteroid hormone also provided a 
potent defense mechanism against volume overload in 
mammals (1).  
The role of glucocorticoids in body fluid and sodium 
metabolism is full of controversy. Traditional teaching 
dedicates that glucocorticoids cause hypertension as a 
consequence of sodium and water retention (2). But, 
newly emerged evidence demonstrated that the rise in 
blood pressure is very likely due to the increased 
pressor responsiveness induced by glucocorticoids 
(3-8). Long term glucocorticoid exposure did not 
increase the occurrence of heart failure in large cohort 
studies (9, 10). A meta-analysis involving 3,793 
patients showed that corticosteroid treatment may be 
beneficial in acute myocardial infarction (11). Mover 
over, contrary to the notion that glucocorticoids cause 
renal water and sodium retention, plenty of evidence 
showed acute glucocorticoid administration could 
produce potent diuresis and natriuresis in rats (1, 8, 12, 
13). In clinical observation, chronic glucocorticoid 
administration could produce potent diuresis and 
restore body fluid homeostasis in heart failure patients 
with severe fluid overload (14-17). However, there 
was no report that long term glucocorticoid treatment 
caused potent diuresis in the subjects other than heart 
failure with fluid overload (9-11). What is the 
mechanism underlying this paradoxical phenomenon? 
Recently, it is revealed that the glucocorticoids can act 
centrally, as well as peripherally, to assist in the 
normalization of extracellular fluid volume. The data 
showed that glucocorticoids not only produced potent 
diuretic effect, but inhibited dehydration-induced 
water intake and sodium depletion-induced sodium 
intake by upregulating the expression of natriuretic 
peptide receptor A (NPR-A) in the kidney and 
hypothalamus, resulted in overt volume depletion (1, 
18, 19). Thus, it is reasonable to assume that the 
diuresis induced by glucocorticoids is systemic 
volume dependent, i.e. the diuresis only appears when 
the patent is under fluid overload status. To elucidate 
the precise mechanism, we designed this study.      
Materials and methods 
Three models with different systemic volume statuses 
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were established, i.e. systemic volume depletion 
model, normal systemic volume model and systemic 
volume overload model, respectively. The rats of three 
models were randomized to receive dexamethasone 
sodium phosphate (Dex, 1mg/kg) or vehicle. The 
urinary volumes were monitored during the study 
period. All animals were managed in accordance with 
the guidelines of the Hebei Medical University, and 
the position of the American Heart Association on 
Research Animal Use. Experimental protocol was 
approved by the Institutional Animal Care and Use 
Committee of Hebei Medical University.  
Systemic volume depletion model 
Twenty intact Wistar rats were deprived of water to 
have their systemic volume depleted. 
Normal systemic volume model  
Twenty intact Wistar rats had free access to water and 
food to have euvolemia. 
Systemic volume overload model 
The post-infarction rat model of heart failure used in 
the study was prepared by the standard method 
previously prescribed (20). The survived rats were 
raised for 12 weeks to have decompensated heart 
failure (i.e. heart failure with fluid overload) (20, 21). 
Statistical analysis 
All the data were express as means ± standard error of 
mean (s.e.m).  
Results 
The data showed that the diuretic effect of Dex was 
more persistent in the systemic volume overload status 
compared with those rats with systemic volume 
depletion or euvolemia. The diuretic effect of one dose 
of Dex peaked at 6 hours after Dex treatment in water 
deprived rats and lasted only 12 hours, whereas it 
peaked at 18 hours and lasted for as much as 45 hours 
in rats with systemic volume overload. The diuretic 
effect induced by Dex in the rats with normal 
hydration was in between (Fig 1A, B, and C).  
Discussion 
The data presented in the paper showed that the 
diuresis induced by glucocorticoids was systemic 
volume dependent, i.e. glucocorticoids only produced 
potent and persistent diuresis in the subjects with 
systemic volume overload. 
 
Figure 1. Diuresis induced by glucocorticoids in 
various volume statuses.  
[A] Diuresis induced by one dose of Dex in rats 
deprived of water. [B] Diuresis induced by one dose 
of Dex in rats given free access to water. [C] Diuresis 
induced by on dose of Dex in rats with heart failure 
given free access to water.  
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The published data about glucocorticoids in body fluid 
metabolism have been confusing. Plenty of evidence 
showed that glucocorticoids could produce potent 
diuretic effect in patients with congestive heart failure 
(14-17); whereas large cohort studies did not 
document this effect in the patients without heart 
failure (9-11). Our finding, i.e. the diuresis induced by 
glucocorticoids is systemic volume dependent, 
provided an answer for the confusing data.  
 
Figure 2. Schematic diagram of the 
glucocorticoids' role in control of body fluid. 
 
The role of glucocorticoids in body fluid 
control 
The diuresis induced by glucocorticoids is systemic 
volume dependent because they can centrally inhibit 
water drinking and salt appetite. Since the discovery 
of atrial natriuretic peptide (ANP), a peptide hormone 
secreted by the atrial myocytes in response to volume 
expansion, the vital role of ANP and its analogs in 
body fluid control is well recognized. They provided a 
potent mechanism counterbalancing the salt- and 
water-retaining actions of the 
renin–angiotensin–aldosterone system in mammals. 
ANP is localized mostly in the heart, but ANP and 
NPR-A, are also found in the kidney and 
hypothalamic areas involved in body fluid volume 
control. Blood volume expansion acts not only 
directly on the heart, by stretch of atrial myocytes to 
increase the release of ANP, but also on the brain 
ANPergic neurons through afferent inputs from 
baroreceptors. Renal NPR-A activation induces potent 
diuresis and natriuresis, whereas hypothalamic NPR-A 
activation produces potent inhibitory effects on water 
drinking (22-24). They work in concert to prevent the 
body from fluid overload. Our recent findings showed 
that glucocorticoids could upregulate NPR-A 
expression in the hypothalamus and kidney (1, 18). 
Consequently, glucocorticoids could produce potent 
diuresis while dramatically inhibiting water drinking 
and salt intake (1, 19). In rats given ad libitum access 
to water and food, glucocorticoids, such as Dex, can 
greatly increase urinary excretion of water without 
compensatory increases in water drinking, leading to 
systemic volume depletion (1, 12). The central 
inhibitory effects on water and sodium intake have the 
body under status of systemic volume depletion. 
Systemic volume depletion, in turn, compromises the 
subsequent renal water and sodium excretion. This is 
the mechanism that diuresis induced by 
glucocorticoids is systemic volume dependent.  
In conclusion, consistent with ANP’s physiological 
role in body fluid metabolism, glucocorticoids play a 
crucial role in fluid volume control not only by 
blocking the neurogenic mechanisms responsible for 
the stimulation of water intake, but also by stimulating 
potent diuretic action through activating renal 
natriuretic peptide system in the kidney. 
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